Evidence map›Paper›PMID 42621160›Full record

ArticleImmuno-oncology technology2026

Management of systemic lupus erythematosus and antiphospholipid syndrome during CAR-T therapy: insights from two clinical cases.

C Normand, S Almaz, R Stadelmann, M Goodyer, B Navarro, A I Martin Quesada, A Mulvey, P Szturz, B Gentner, L Trueb and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Immuno-oncology technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

C NormandDepartment of Oncology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
S AlmazDepartment of Oncology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
R StadelmannDivision of Hematology, Department of Oncology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
M GoodyerHematology Service, Institut Central des Hôpitaux, Sion, Switzerland.
B NavarroImmuno-Oncology Service, Department of Oncology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
A I Martin QuesadaImmuno-Oncology Service, Department of Oncology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
A MulveyImmuno-Oncology Service, Department of Oncology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
P SzturzImmuno-Oncology Service, Department of Oncology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
B GentnerImmuno-Oncology Service, Department of Oncology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
L TruebImmuno-Oncology Service, Department of Oncology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
C ArberImmuno-Oncology Service, Department of Oncology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
E GhisoniImmuno-Oncology Service, Department of Oncology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
M Le MoineImmuno-Oncology Service, Department of Oncology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) are autoimmune disorders marked by the presence of pathogenic autoantibodies predominantly produced by B cells. Both conditions are chronic, incurable, and require lifelong treatment. Chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a promising treatment for refractory hematological malignancies, with anti-CD19 CAR-T therapy demonstrating high efficacy in relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The profound depletion of B cells induced by anti-CD19 CAR-T therapy suggests that this treatment may influence the clinical course of patients with DLBCL and concomitant SLE or APS. Materials and methods: We report two clinical cases of patients diagnosed with both DLBCL and concomitant SLE and APS who underwent anti-CD19 CAR-T therapy at our institution. We describe the lymphoproliferative disease course as well as the serological evolution and longitudinal cytokine profiles measured before and after CAR-T therapy. Results: In both cases, CAR-T therapy resulted in complete and long-lasting metabolic remission of the lymphoproliferative disorder. Concurrently, autoantibody titers stabilized, permitting stepwise de-escalation of the immunomodulatory treatment. Conclusion: These cases demonstrate that CAR-T therapy for DLBCL is feasible and appears safe in patients with concomitant autoimmune disease but requires close monitoring and interdisciplinary management. These findings support further preclinical and clinical investigation of CAR-T therapy as a potential therapeutic approach in patients with DLBCL and concomitant SLE and APS.

Indexed as

antiphospholipid syndromeCAR-T therapycase reportcytokinessystemic lupus erythematosus

Identifiers

PMID42621160
PMCPMC13486846

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.